Promising Results Announced for an Investigational Drug for Treating Dravet Syndrome

Epilepsy News From: Friday, October 06, 2017

Zogenix, Inc. recently reported positive results for its Phase 3 clinical trial for the drug ZX008 (low-dose fenfluramine hydrochloride) for treating Dravet syndrome. The trial showed that at a dose of 0.8 mg/kg/day, ZX008 performed better as an add-on seizure medication compared to a placebo for changing the number of monthly convulsive (for example, tonic clonic) seizures. A higher proportion of participants on this dose also had reductions in seizure frequency and experienced longer seizure-free periods. ZX008 also showed improvement over a placebo at a dose of 0.2 mg/kg/day.

More Information on the Study

  • The study included 119 participants across the United States, Canada, Europe, and Australia
  • Median age of participants was 8 years
  • Participants were placed into three treatment groups where either ZX008 0.8 mg/kg/day, ZX008 0.2 mg/kg/day, or a placebo was added to their current therapies. Participants remained at a fixed dose for 12 weeks.
  • Participants on the 0.8 dose had a 63.9% reduction in average monthly seizures compared to the placebo. Participants on the 0.2 dose had 33.7% reduction in average monthly seizures.
  • Both non-placebo groups experienced adverse events more often than the placebo group (95% vs. 65%).

Join a Clinical Trial

The Fenfluramine Assessment in Rare Epilepsy (FAiRE) clinical trials are currently recruiting children and young adults with Dravet syndrome.

Reviewed Date

Friday, October 06, 2017

Join Our Newsletter

Want to get notified about new devices? Stay up to date with the latest epilepsy news and stories from the community.